News - Appointments

UK-based e-Therapeutics Plc has appointed Laura Roca-Alonso as chief business officer following an executive restructuring at the company that earlier saw Ali Mortazavi, the former chief executive of Silence Therapeutics Plc, become exe

Sergio Quezada, an inventor and professor of cancer immunology, has become chief scientific officer of Achilles Therapeutics Ltd, a company that+ he helped found in 2016.

Arndt Schottelius, a veteran biotech executive, has been appointed chief scientific officer at Affimed NV to lead development of the company’s portfolio of innate cell engager-based medicines for cancer, and to manage its partnerships.

Genmab A/S has recruited Anthony Mancini to the newly created position of chief operating officer to oversee its commercial, corporate and business development as the company progresses more antibody therapies for cancer towards the mar

Mitchell Harris, a former executive at Abcam Plc, has joined Genomics Plc as chief strategy officer to help the genetics and data science company discover new drugs.

Immune Regulation Ltd has appointed Jonathan Rigby as its chief executive and member of the board of directors. Formerly known as Peptinnovate, Immune Regulation is developing therapies for inflammatory and immunological diseases.

Stefanos Theoharis, an experienced cell therapy executive, has joined Bone Therapeutics SA as chief business officer to help partner the company’s programmes, in-license assets and advance the proprietary portfolio.

Malcolm Weir has been promoted to the role of executive vice chairman of Sosei Group Corp with responsibility for strategic oversight of all platform technology, R&D and early drug development at Sosei Heptares, the Japanese company

Jean Richard de la Tour, an experienced jurist, has been appointed Advocate General of the Court of Justice of the European Union to succeed Yves Bot who died on 9 June 2019. He will hold the position until 6 October 2024.

Medicxi, the European life sciences investment firm, has appointed two US executives, Sanford Zweifach and Paul Sekhri, as venture partners to lead development of the fund’s portfolio companies.